Abstract Search

hrp0098p1-63 | Growth and Syndromes 1 | ESPE2024

Long-term effectiveness and safety data from the Global Increlex^® Registry in patients treated with rhIGF-1: Subgroup analysis of naïve pre-pubertal patients and patients with Laron syndrome

Ramón Krauel Marta , Woelfe Joachim , Polak Michel , Maghnie Mohamad , Beń-Skowronek Iwona , Sert Caroline , Perrot Valérie , Bang Peter

Background: The Global Increlex® Registry (NCT00903110) monitors real-world safety and effectiveness of recombinant human insulin-like growth factor (rhIGF-1; Increlex® [mecasermin]) in severe primary IGF-1 deficiency (SPIGFD). Patient characteristics, effectiveness and safety data from 2008–2023 are described.Methods: Descriptive analyses of registry data from children/adolescents age...

0 shares

hrp0098fc5.6 | Growth and Syndromes | ESPE2024

First line treatment evaluation in patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD): Data from the Global Increlex^® Registry

Bang Peter , Backeljauw Philippe , Woelfe Joachim , Bossowski Artur , Beń-Skowronek Iwona , Argente Jesús , De Schepper Jean , Perrot Valérie , Sert Caroline , Maghnie Mohamad

Background: Severe primary insulin-like growth factor-1 deficiency (SPIGFD) is a rare growth disorder characterised by extreme short stature, low serum IGF-1 and normal/elevated serum growth hormone (GH). Some patients receive GH treatment before recombinant human IGF-1 (rhIGF-1; Increlex® [mecasermin]). We investigated rhIGF-1 effectiveness and tolerability in patients previously treated with GH versus GH naïve patients at rhIGF-1 initiati...

1 shares

ESPE Abstracts

Long-term effectiveness and safety data from the Global Increlex^® Registry in patients treated with rhIGF-1: Subgroup analysis of naïve pre-pubertal patients and patients with Laron syndrome

First line treatment evaluation in patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD): Data from the Global Increlex^® Registry

BiosciAbstracts

ESPE Abstracts

Long-term effectiveness and safety data from the Global Increlex® Registry in patients treated with rhIGF-1: Subgroup analysis of naïve pre-pubertal patients and patients with Laron syndrome

First line treatment evaluation in patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD): Data from the Global Increlex® Registry

BiosciAbstracts

Long-term effectiveness and safety data from the Global Increlex^® Registry in patients treated with rhIGF-1: Subgroup analysis of naïve pre-pubertal patients and patients with Laron syndrome

First line treatment evaluation in patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD): Data from the Global Increlex^® Registry